Abstract
Drug discovery is costly and time-consuming, but it will become easier and simpler if a drug could be developed from an old one with well-documented investigations associated with pharmacology, pharmacokinetics, toxicology and clinical safety. In terms of hematological malignancies, several successful drugs have been discovered and developed from old ones such as arsenic trioxide for acute promyelocytic leukemia and thalidomide for multiple myeloma. In this review, we discussed the latest advancement in exploring old drugs for the treatment of hematological malignancies.
Keywords: Drug repositioning, drug discovery, old drug, hematological malignancy, drug, arsenic trioxide, pharmacological, therapeutic, dysfunction, methotrexate, rheumatoid arthritis, hematological malignancies
Current Medicinal Chemistry
Title: Exploring Old Drugs for the Treatment of Hematological Malignancies
Volume: 18 Issue: 10
Author(s): F. Gan, B. Cao, D. Wu, Z. Chen, T. Hou and X. Mao
Affiliation:
Keywords: Drug repositioning, drug discovery, old drug, hematological malignancy, drug, arsenic trioxide, pharmacological, therapeutic, dysfunction, methotrexate, rheumatoid arthritis, hematological malignancies
Abstract: Drug discovery is costly and time-consuming, but it will become easier and simpler if a drug could be developed from an old one with well-documented investigations associated with pharmacology, pharmacokinetics, toxicology and clinical safety. In terms of hematological malignancies, several successful drugs have been discovered and developed from old ones such as arsenic trioxide for acute promyelocytic leukemia and thalidomide for multiple myeloma. In this review, we discussed the latest advancement in exploring old drugs for the treatment of hematological malignancies.
Export Options
About this article
Cite this article as:
Gan F., Cao B., Wu D., Chen Z., Hou T. and Mao X., Exploring Old Drugs for the Treatment of Hematological Malignancies, Current Medicinal Chemistry 2011; 18 (10) . https://dx.doi.org/10.2174/092986711795328427
DOI https://dx.doi.org/10.2174/092986711795328427 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acyl Thiourea Derivatives Containing Pyrazole Ring Selective Targeting of Human Aurora Kinases in Breast and Bone Cancer
Letters in Drug Design & Discovery Anti Tumor Necrosis Factor Alpha (TNFα) Therapy in Ankylosing Spondylitis - Asian Perspective
Current Rheumatology Reviews Monoclonal Antibodies in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents RANKL/RANK/OPG: Key Therapeutic Target in Bone Oncology
Current Drug Discovery Technologies Post-Wortmannin Era: Novel Phosphoinositide 3-Kinase Inhibitors with Potential Therapeutic Applications
Current Enzyme Inhibition Immunomodulatory Drugs as a Therapy for Multiple Myeloma
Current Pharmaceutical Biotechnology Dendritic Cells and their Receptors in Antitumor Immune Response
Current Molecular Medicine Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms
Cardiovascular & Hematological Disorders-Drug Targets Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Study of Common Bacterial and Fungal Pathogens in Children with Hematological Malignancies during Febrile Neutropenia: Single Center Egyptian Study
Infectious Disorders - Drug Targets Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry Development of DNA Methyltransferase Inhibitors for the Treatment of Neoplastic Diseases
Current Medicinal Chemistry Exploiting APC Function as a Novel Cancer Therapy
Current Drug Targets Proteasome Inhibition in Transplantation-Focusing on the Experience with Bortezomib
Current Pharmaceutical Design Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer
Current Cancer Therapy Reviews Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase
Recent Patents on Anti-Cancer Drug Discovery Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment
Current Drug Targets A Personalized Approach to Systemic Treatment of Unresectable or Metastatic Pancreatic Adenocarcinoma
Current Pharmacogenomics and Personalized Medicine Tumor Invasion and Oxidative Stress: Biomarkers and Therapeutic Strategies
Current Molecular Medicine